Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
August 2025 : The US FDA approved Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced-calorie diet and increased physical activity
In terms of weight loss, scientists reported female participants lost an average of 9.6% of their body weight, compared to male participants who lost an average of 7.2%
How accurate are the calculations
Initially approved for the treatment of type 2 diabetes, it has shown remarkable efficacy in weight management
More frequent dosing means more injection supplies to pack and more opportunities for schedule disruption during travel
5 questions to ask before restarting a GLP-1 postpartum When is the right time for me, given my recovery and feeding plan
